Sildenafil-Statin Use Linked to 31% Lower 5-Year Cancer Death Risk in 40,000 Men
Updated
Updated · studyfinds.com · Aug 6
Sildenafil-Statin Use Linked to 31% Lower 5-Year Cancer Death Risk in 40,000 Men
3 articles · Updated · studyfinds.com · Aug 6
Summary
More than 40,000 male cancer patients in Israeli health records showed a 31% lower risk of death within five years when sildenafil and statins were used together, versus neither drug.
Cancer Research experiments tied that signal to mechanism: sildenafil blocked PDE5a, raised cGMP and jammed NPC1-driven cholesterol transport, leaving cancer cells short of usable cholesterol needed to migrate and spread.
Mouse studies in breast, lung and colon cancer models found fewer lung metastases, while adding lovastatin further reduced cancer-cell movement and colony growth and increased cell death compared with either drug alone.
The human evidence remains observational—cancer stage was unavailable and some sildenafil use may have gone uncaptured—so the study stops short of proving causation.
Researchers say the combined lab, animal and patient-record findings justify clinical trials of sildenafil plus statins as a potential add-on to existing cancer treatment.